[Hydroxymethyluracil in the correction of adverse effects caused by chemotherapy of malignant neoplasms].

Abstract

Hydroxymethyluracil (HMU) in a dose of 1.5-3 g/day produces a stimulant effect upon leukopoiesis and granulocytopoiesis in cases of toxic neutropenia caused by chemotherapy. In the same dose range, HMU produces immunostimulant action in patients with immune deficit caused by oncopathology and chemotherapy.

• Authors: D D Sakaeva
• Journal: Eksperimental'naia i klinicheskaia farmakologiia (Eksp Klin Farmakol) 2004 Jan-Feb Vol. 67 Issue 1 Pg. 51-3 ISSN: 0869-2092 [Print] Russia (Federation)
• Vernacular Title: Oksimetiluratsil kak korrektor oslozhneniĭ khimioterapii zlokachestvennykh opukholeĭ.
• PMID: 15079911 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Adjuvants, Immunologic
• Antineoplastic Agents
• 5-hydroxymethyluracil
• Pentoxyl

Topics

• Adjuvants, Immunologic (pharmacology, therapeutic use)
• Adolescent
• Adult
• Aged
• Antineoplastic Agents (adverse effects)
• Humans
• Lymphoma (drug therapy, immunology)
• Middle Aged
• Neoplasms (drug therapy, immunology)
• Neutropenia (chemically induced, drug therapy, immunology)
• Pentoxyl (analogs & derivatives, pharmacology, therapeutic use)